Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omic...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Metabolism Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589936822000184 |
| _version_ | 1818212818159140864 |
|---|---|
| author | Evropi Amanatidou Anna Gkiouliava Eva Pella Maria Serafidi Dimitrios Tsilingiris Natalia G. Vallianou Ιrene Karampela Maria Dalamaga |
| author_facet | Evropi Amanatidou Anna Gkiouliava Eva Pella Maria Serafidi Dimitrios Tsilingiris Natalia G. Vallianou Ιrene Karampela Maria Dalamaga |
| author_sort | Evropi Amanatidou |
| collection | DOAJ |
| description | Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since “breakthrough” infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission. |
| first_indexed | 2024-12-12T05:54:26Z |
| format | Article |
| id | doaj.art-d525120d65b445cb9f3db0e03fbffbad |
| institution | Directory Open Access Journal |
| issn | 2589-9368 |
| language | English |
| last_indexed | 2024-12-12T05:54:26Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Metabolism Open |
| spelling | doaj.art-d525120d65b445cb9f3db0e03fbffbad2022-12-22T00:35:36ZengElsevierMetabolism Open2589-93682022-06-0114100180Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challengesEvropi Amanatidou0Anna Gkiouliava1Eva Pella2Maria Serafidi3Dimitrios Tsilingiris4Natalia G. Vallianou5Ιrene Karampela6Maria Dalamaga7Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, GreeceLaboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, GreeceLaboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, GreeceLaboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, GreeceFirst Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, GreeceFirst Department of Internal Medicine, Evangelismos General Hospital, Athens, GreeceSecond Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, Chaidari, Athens, GreeceDepartment of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, Greece; Corresponding author.Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since “breakthrough” infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission.http://www.sciencedirect.com/science/article/pii/S2589936822000184AntibodyBreakthrough infectionCOVID-19ImmunityNeutralizing antibodyOmicron |
| spellingShingle | Evropi Amanatidou Anna Gkiouliava Eva Pella Maria Serafidi Dimitrios Tsilingiris Natalia G. Vallianou Ιrene Karampela Maria Dalamaga Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges Metabolism Open Antibody Breakthrough infection COVID-19 Immunity Neutralizing antibody Omicron |
| title | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
| title_full | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
| title_fullStr | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
| title_full_unstemmed | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
| title_short | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
| title_sort | breakthrough infections after covid 19 vaccination insights perspectives and challenges |
| topic | Antibody Breakthrough infection COVID-19 Immunity Neutralizing antibody Omicron |
| url | http://www.sciencedirect.com/science/article/pii/S2589936822000184 |
| work_keys_str_mv | AT evropiamanatidou breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT annagkiouliava breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT evapella breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT mariaserafidi breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT dimitriostsilingiris breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT nataliagvallianou breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT irenekarampela breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT mariadalamaga breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges |